In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In the latest session, Outlook Therapeutics Inc (NASDAQ: OTLK) closed at $1.86 up 3.91% from its previous closing price of $1.79. In other words, the price has increased by $3.91 from its previous closing price. On the day, 1.48 million shares were traded. OTLK stock price reached its highest trading level at $1.875 during the session, while it also had its lowest trading level at $1.75.
Ratios:
For a deeper understanding of Outlook Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.54 and its Current Ratio is at 0.67.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OTLK now has a Market Capitalization of 82620320 and an Enterprise Value of 108417216. For the stock, the TTM Price-to-Sale (P/S) ratio is 54.71. Its current Enterprise Value per Revenue stands at 72.023 whereas that against EBITDA is -1.495.
Stock Price History:
The Beta on a monthly basis for OTLK is 0.18, which has changed by -0.008310258 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, OTLK has reached a high of $3.39, while it has fallen to a 52-week low of $0.79. The 50-Day Moving Average of the stock is 37.94%, while the 200-Day Moving Average is calculated to be 17.62%.
Shares Statistics:
For the past three months, OTLK has traded an average of 3.52M shares per day and 4715830 over the past ten days. A total of 43.48M shares are outstanding, with a floating share count of 29.09M. Insiders hold about 34.52% of the company’s shares, while institutions hold 9.11% stake in the company. Shares short for OTLK as of 1763078400 were 4060839 with a Short Ratio of 1.15, compared to 1760486400 on 2168058. Therefore, it implies a Short% of Shares Outstanding of 4060839 and a Short% of Float of 11.1.
Earnings Estimates
. The current rating of Outlook Therapeutics Inc (OTLK) reflects the combined expertise of 4.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.09 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.72 and -$1.92 for the fiscal current year, implying an average EPS of -$1.84. EPS for the following year is -$1.01, with 4.0 analysts recommending between -$0.28 and -$1.67.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of $4.4M. There is a high estimate of $5M for the next quarter, whereas the lowest estimate is $3.8M. Based on 5 analysts’ estimates, the company’s revenue will be $29.78M in the next fiscal year. The high estimate is $60.88M and the low estimate is $15.92M.
